[1] |
Visbal AL, Leighl NB, Feld R, et al. Adjuvant chemotherapy for early-stage non-small cell lung cancer[J]. Chest,2005,128(4):2933 -43.
|
[2] |
Scagliotti GV, Parikh P, von Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oncol, 2008,26(21):3543-51.
|
[3] |
Ma J, Huo JG. Recent progress in anti-tumor effect of Celecoxib[J]. Xian Dai Zhong Liu Yi Xue,2012,20(5):1059-61.[马骏, 霍介格. 塞来昔布抗肿瘤作用研究进展[ J ] . 现代肿瘤 学,2012,20(5):1059-61.]
|
[4] |
Benoit V, de Moraes E, Dar NA, et al. Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB[J]. Oncogene, 2006, 25(42):5708-18.
|
[5] |
Harris RE. Cyclooxygenase-2 ( cox-2) and the inflammogenesis of cancer[J]. Subcell Biochem,2007,42: 93-126.
|
[6] |
Liu H, Yang Y, Xiao J, et al. COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer[J]. Anat Rec (Hoboken), 2010, 29 3(11):1836-46.
|
[7] |
Haynes A, Shaik MS, Chatterjee A, et al. Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer[J]. Pharm Res, 2005, 22(3):427-39.
|
[8] |
Koch A, Bergman B, Holmberg E, et al. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase Ⅲ trial (CYCLUS study) by the Swedish Lung Cancer Study Group[J]. Eur J Cancer, 2011, 47 (10):1546-55.
|
[9] |
Liu CH, Bao HG, Ge YL, et al. Celecoxib inhibits insulin-like growth factor 1 induced growth and invasion in non-small cell lung cancer[J]. Oncol Lett, 2013, 5(6):1943-7.
|
[10] |
Gasparini G, Meo S, Comella G, et al. The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase Ⅱ study with biological correlates[J]. Cancer J, 2005, 11(3):209-16.
|
[11] |
Nugent FW, Mertens WC, Graziano S, et al. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase Ⅱ trial[J]. Lung Cancer, 2005, 48 (2):267-73.
|
[12] |
Schneider BJ, Kalemkerian GP, Kraut MJ, et al. Phase Ⅱ study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy[J]. J Thorac Oncol, 2008, 3(12):1454-9.
|
[13] |
Gadgeel SM, Wozniak A, Ruckdeschel JC, et al. Phase Ⅱ study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced nonsmall cell lung cancer[J]. J Thorac Oncol, 2008, 3(11):1293-300.
|
[14] |
Fidler MJ, Argiris A, Patel JD, et al. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib[J]. Clin Cancer Res,2008, 14(7):2088-94.
|
[15] |
Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203[J]. J Clin Oncol, 2008, 26 (6):848-55.
|
[16] |
Groen HJ, Sietsma H, Vincent A, et al. Randomized, placebocontrolled phase Ⅲ study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study[J]. J Clin Oncol, 2011, 29(32):4320-6.
|
[17] |
Lei JH,Hong T, Zeng JZ.Clinical observation of cyclooxygenase-2 inhibitor celecoxib combined with oxycontin in treatment of moderate and severe cancer pain[J]. Lin Chuang Wu Zhen Wu Zhi, 2013,26(7):83-5. [雷俊华,洪涛,曾江正. 塞来昔布 联合奥施康定治疗中重度癌痛的临床观察[J]. 临床误诊误 治,2013,26(7):83-5.]
|
[18] |
Dong XF, Hu XY, Du FM, et al. The efficacy of oxycontin combined with celecoxib in the treatment for cancer pain with moderate to severe degree[J].Zhong Liu Xue Za Zhi, 20 13,19(8):654-6. [董小芳,胡晓燕,杜方民,等. 奥施康定 联合塞来昔布治疗中重度癌痛的疗效分析[ J ] . 肿瘤学杂 志,2013,19(8):654-6.]
|